Get the Stockscreener App
4.38
12.31%
0.48
After Hours:
4.26
-0.12
-2.74%
Kodiak Sciences Inc stock is traded at $4.38, with a volume of 596.18K.
It is up +12.31% in the last 24 hours and up +64.66% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
See More
Previous Close:
$3.90
Open:
$3.89
24h Volume:
596.18K
Relative Volume:
3.01
Market Cap:
$205.20M
Revenue:
-
Net Income/Loss:
$-260.49M
P/E Ratio:
-0.7684
EPS:
-5.7
Net Cash Flow:
$-195.61M
1W Performance:
+11.45%
1M Performance:
+64.66%
6M Performance:
+16.18%
1Y Performance:
+85.59%
1-Day Range:
$3.89
$4.40
1-Week Range:
$3.725
$4.40
52-Week Range:
$1.59
$7.77
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences (KOD) Price Target Increased by 25.00% to 5.10 - MSN
Zacks Research Raises Earnings Estimates for Kodiak Sciences - MarketBeat
Age-related Macular Degeneration Market Size is Set for Rapid - openPR
Sanctuary Advisors LLC Purchases New Holdings in Denny’s Co. (NASDAQ:DENN) - Defense World
3 US Penny Stocks With Market Caps Under $500M To Consider - Simply Wall St
Financial Comparison: Kodiak Sciences (NASDAQ:KOD) & Fennec Pharmaceuticals (NASDAQ:FENC) - Defense World
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update - MarketBeat
Pacific Seafood to take over Trident Seafoods’ Kodiak operations - just-food.com
Campaigning begins for Japan's parliamentary election - 69News WFMZ-TV
KODKodiak Sciences Inc Latest Stock News & Market Updates - StockTitan
Kodiak Sciences to Present at Innovate Retina 2024 - StockTitan
Retinal Vein Occlusion Market Size is Set for Rapid Growth as - openPR
Expect employers to get more picky about who you see for care - 69News WFMZ-TV
Documents show OpenAI's long journey from nonprofit to $157B valued company - 69News WFMZ-TV
Could Certain Genes Help You Slim Down? - 69News WFMZ-TV
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks - Yahoo Finance
Having COVID-19 doubles risk of heart attack or stroke: study - 69News WFMZ-TV
VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - GlobeNewswire
Innovator U.S. Equity Accelerated 9 Buffer ETF – January (BATS:XBJA) Shares Sold by Cetera Investment Advisers - Defense World
Vanguard Personalized Indexing Management LLC Buys Shares of 17,896 Redfin Co. (NASDAQ:RDFN) - Defense World
Natural Grocers by Vitamin Cottage (NYSE:NGVC) Stock Price Up 4.8% - Defense World
Susquehanna Portfolio Strategies LLC Has $330,000 Stake in SandRidge Energy, Inc. (NYSE:SD) - Defense World
Kodiak Sciences' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com South Africa
Xponance Inc. Sells 12,667 Shares of Mattel, Inc. (NASDAQ:MAT) - Defense World
Inozyme Pharma (NASDAQ:INZY) Earns Outperform Rating from Wedbush - Defense World
Retinal Disorder Treatment Market Share Report, Industry Share and Trends Analysis By 2033 - WhaTech
Data Storage (NASDAQ:DTST) Stock Quotes, Forecast and News Summary - Benzinga
Evergreen Capital Management LLC Raises Position in Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NYSE:HASI) - Defense World
Retinal Biologics Market Advancements Highlighted by Size, Share Analysis And Forecast Report 2024 To 2033 - WhaTech
Goldman Sachs maintains sell rating on Kodiak Sciences stock By Investing.com - Investing.com South Africa
Goldman Sachs maintains sell rating on Kodiak Sciences stock - Investing.com
Kodiak Sciences (NASDAQ:KOD) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time - StockTitan
Psilocybin Equals or Exceeds SSRI Antidepressants at Easing Depression - 69News WFMZ-TV
Cataracts Gone Without Surgery? New Science Suggests It's Possible - 69News WFMZ-TV
Could Antidepressants Give Memory a Boost? - 69News WFMZ-TV
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully - Yahoo Finance
Stock market today: Wall Street stays stuck in place as it counts down to a rate cut - 69News WFMZ-TV
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City - StockTitan
Health Beat: Giving hope to melanoma patients - 69News WFMZ-TV
Google says it will rethink its plans for a big data center in Chile over water worries - 69News WFMZ-TV
More Cancer Cases in Areas Where Incarceration Rates Are High: Study - 69News WFMZ-TV
Logan Paul and MrBeast launch a Lunchables competitor that they say is healthy - 69News WFMZ-TV
A Few Cups of Coffee Per Day Might Help Your Heart - 69News WFMZ-TV
Nearly 2 in 5 Americans at peak stress levels - 69News WFMZ-TV
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report? - MSN
Pivotal Research Initiates Coverage of TKO Group Holdings (TKO) with Buy Recommendation - MSN
Acadian Asset Management LLC Raises Stake in Kodiak Sciences Inc. (NASDAQ:KOD) - MarketBeat
Rimini Street, Inc. (NASDAQ:RMNI) Shares Bought by Acadian Asset Management LLC - Defense World
Strategic Financial Concepts LLC Purchases New Position in Prosperity Bancshares, Inc. (NYSE:PB) - Defense World
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | See Remarks |
Jun 12 '24 |
Sale |
2.92 |
1,558 |
4,549 |
179,544 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):